Cargando…

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection fraction, associated with undertreatment and worse outcomes. New treatments for heart failure with reduced ejection fraction may be particularly important in patients with concomit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehteshami‐Afshar, Solmaz, Mooney, Leanne, Dewan, Pooja, Desai, Akshay S., Lang, Ninian N., Lefkowitz, Martin P., Petrie, Mark C., Rizkala, Adel R., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Shi, Victor C., Zile, Michael R., Packer, Milton, McMurray, John J. V., Jhund, Pardeep S., Hawkins, Nathaniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955331/ https://www.ncbi.nlm.nih.gov/pubmed/33522249 http://dx.doi.org/10.1161/JAHA.120.019238

Ejemplares similares

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
por: Mooney, Leanne, et al.
Publicado: (2021)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
por: Shen, Li, et al.
Publicado: (2021)

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
por: Kondo, Toru, et al.
Publicado: (2022)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
por: Rørth, Rasmus, et al.
Publicado: (2018)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
por: Dewan, Pooja, et al.
Publicado: (2018)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.
por: Ramires, Felix J.A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_of7ruqgksn7h5l167cc3df0023